What is ELDN's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.20B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for ELDN?

P/E (TTM) is n/a and 52-week range is $1.35 to $4.60 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s ELDN figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for ELDN?

The company profile lists net income (TTM) near $-74M, EPS (TTM) near $-0.96 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Eledon Pharmaceuticals Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Irvine, California, US, 77.2M shares outstanding, ISIN US28617K1016 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Eledon Pharmaceuticals Inc

$ELDN

Health Care · Biotechnology

IR Run Scenarios

$2.48

+2.48%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company, which engages in development of therapies to protect transplanted organs and prevent rejection. The company is headquartered in Irvine, California and currently employs 33 full-time employees. The company went IPO on 2014-09-17. The firm is developing immune-modulating therapies for the management and treatment of life-threatening conditions. The Company’s lead investigational product is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for CD40 Ligand, a well-validated biological target within the costimulatory CD40/CD40L cellular pathway. The central role of CD40L signaling in both adaptive and innate immune cell activation and function positions it as an attractive target for non-lymphocyte depleting, immunomodulatory therapeutic intervention. Tegoprubart is engineered to potentially both improve safety and provides pharmacokinetic, pharmacodynamic, and dosing advantages. CD40L is primarily expressed on activated CD4+ T cells, platelets, and endothelial cells while the CD40 receptor is constitutively expressed on antigen-presenting cells, such as macrophages and dendritic cells, as well as B cells.

Employees

Website

eledon.com/

IPO

2014-09-17

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)